Clinical Trial Update: Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of Erdafitinib in castration-resistant prostate cancer was terminated; the document provides the status update without reported results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer
• Small Cell Neuroendocrine Carcinoma of the Prostate

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents | Phase 2 | Status: TERMINATED